echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The second phase of SAGE-324 essential tremor was successful

    The second phase of SAGE-324 essential tremor was successful

    • Last Update: 2021-05-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today Sage announced that its GABAA receptor positive modulator SAGE-324 has reached its primary endpoint in a phase II clinical trial of essential tremor.


    Drug source analysis

    Essential tremor is the most common muscle dysfunction.


    It is generally believed that essential tremor and epilepsy are caused by central electrophysiological disorders, and Sage's central steroid series of drugs were originally designed for rare epilepsy.


    Both types of drugs have an effect on sleep, and drowsiness and dizziness can be said to be mechanism-related side effects.


    SAGE-324 is not the core asset of Sage.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.